Patents by Inventor E. Christopher Orton
E. Christopher Orton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210386542Abstract: This invention relates to the design and function of a compressible valve replacement prosthesis which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.Type: ApplicationFiled: August 27, 2021Publication date: December 16, 2021Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, AVALON MEDICAL, LTD.Inventors: Kemal Schankereli, E. Christopher Orton
-
Patent number: 11179236Abstract: This invention relates to the design and function of a compressible valve replacement prosthesis which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.Type: GrantFiled: May 24, 2016Date of Patent: November 23, 2021Assignees: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, AVALON MEDICAL, LTD.Inventors: Kemal Schankereli, E. Christopher Orton
-
Publication number: 20160262881Abstract: This invention relates to the design and function of a compressible valve replacement prosthesis which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.Type: ApplicationFiled: May 24, 2016Publication date: September 15, 2016Applicants: Colorado State University Research Foundation, Avalon Medical, Ltd.Inventors: Kemal SCHANKERELI, E. Christopher ORTON
-
Patent number: 8425504Abstract: A method for cardiac surgical intervention relies on sealing or fusing heart valve leaflets without requiring implanted materials such as sutures or staples. The method provides a forceps having at least one shaft and an end effector assembly attached thereto. The end effector assembly includes a pair of opposing jaw members configured to move from an open, spread position to a closed, grasping position; creating at least one opening in the patient for inserting the forceps therein; inserting through the opening and manipulating jaw members of the forceps to grasp a portion of a first heart valve leaflet and a portion of a second heart valve leaflet therebetween; activating the forceps to close the jaw members about the leaflet portions under a working pressure, applying radiofrequency energy to the jaw members to seal the portion of the first heart valve leaflet to the portion of the second heart valve leaflet.Type: GrantFiled: November 30, 2011Date of Patent: April 23, 2013Assignee: Covidien LPInventors: E. Christopher Orton, Michael C. Moses, Amy Denham, Jeffrey R. Townsend
-
Publication number: 20120179244Abstract: This invention relates to the design and function of a compressible valve replacement prosthesis which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.Type: ApplicationFiled: March 21, 2012Publication date: July 12, 2012Inventors: Kemal Schankereli, E. Christopher Orton
-
Publication number: 20120078250Abstract: A method for cardiac surgical intervention relies on sealing or fusing heart valve leaflets without requiring implanted materials such as sutures or staples. The method provides a forceps having at least one shaft and an end effector assembly attached thereto. The end effector assembly includes a pair of opposing jaw members configured to move from an open, spread position to a closed, grasping position; creating at least one opening in the patient for inserting the forceps therein; inserting through the opening and manipulating jaw members of the forceps to grasp a portion of a first heart valve leaflet and a portion of a second heart valve leaflet therebetween; activating the forceps to close the jaw members about the leaflet portions under a working pressure, applying radiofrequency energy to the jaw members to seal the portion of the first heart valve leaflet to the portion of the second heart valve leaflet.Type: ApplicationFiled: November 30, 2011Publication date: March 29, 2012Applicant: TYCO Healthcare Group LPInventors: E. Christopher Orton, Michael C. Moses, Amy Denham, Jeffrey R. Townsend
-
Patent number: 8133168Abstract: A dynamic device for reducing functional mitral regurgitation is described. The device is disposed externally to the heart and effectively acts as a splint for reducing further dilation of the heart in patients diagnosed with cardiomyopathy, and for reducing tethering of the papillary muscle on the mitral valve. The device does not require cardiopulmonary bypass for its installation since it is attached to the outside of the left ventricle, thereby reducing surgical risk, and is not exposed to the patient's blood once installed, thereby reducing the risk of thromboembolic disease.Type: GrantFiled: September 1, 2006Date of Patent: March 13, 2012Assignee: Colorado State University Research FoundationInventors: Eric Monnet, E. Christopher Orton, Susan P. James, Kyle Garrett Ordway, John Ordway, legal representative
-
Publication number: 20110319988Abstract: This invention relates to the design and function of a compressible valve replacement prosthesis which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.Type: ApplicationFiled: December 8, 2010Publication date: December 29, 2011Inventors: Kemal Schankereli, E. Christopher Orton
-
Patent number: 8070746Abstract: A method for cardiac surgical intervention relies on sealing or fusing heart valve leaflets without requiring implanted materials such as sutures or staples. The method provides a forceps having at least one shaft and an end effector assembly attached thereto. The end effector assembly includes a pair of opposing jaw members configured to move from an open, spread position to a closed, grasping position; creating at least one opening in the patient for inserting the forceps therein; inserting through the opening and manipulating jaw members of the forceps to grasp a portion of a first heart valve leaflet and a portion of a second heart valve leaflet therebetween; activating the forceps to close the jaw members about the leaflet portions under a working pressure, applying radiofrequency energy to the jaw members to seal the portion of the first heart valve leaflet to the portion of the second heart valve leaflet.Type: GrantFiled: May 25, 2007Date of Patent: December 6, 2011Assignee: TYCO Healthcare Group LPInventors: E. Christopher Orton, Michael C. Moses, Amy Denham, Jeffrey Townsend
-
Publication number: 20110236949Abstract: Methods are provided for removing or separating the cellular and/or soluble macromolecular component of a biological tissue from the extracellular matrix component of the biological tissue, comprising embedding the biological tissue in an electrically conductive semi-solid or solid supporting medium and applying an electric field to the tissue-medium complex. Additionally, methods are provided for decellularizing a skin fragment.Type: ApplicationFiled: September 22, 2010Publication date: September 29, 2011Applicant: COLORADO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: E. Christopher Orton, Shiori Arai, Carla Maria Ribeiro Lacerda, Leigh Gareth Griffiths
-
Publication number: 20090287037Abstract: A dynamic device for reducing functional mitral regurgitation is described. The device is disposed externally to the heart and effectively acts as a splint for reducing further dilation of the heart in patients diagnosed with cardiomyopathy, and for reducing tethering of the papillary muscle on the mitral valve. The device does not require cardiopulmonary bypass for its installation since it is attached to the outside of the left ventricle, thereby reducing surgical risk, and is not exposed to the patient's blood once installed, thereby reducing the risk of thromboembolic disease.Type: ApplicationFiled: September 1, 2006Publication date: November 19, 2009Applicant: COLORADO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Eric Monnet, E. Christopher Orton, Susan P. James, Kyle Garrett Ordway, John Ordway
-
Publication number: 20080082100Abstract: A method for cardiac surgical intervention relies on sealing or fusing heart valve leaflets without requiring implanted materials such as sutures or staples. The method provides a forceps having at least one shaft and an end effector assembly attached thereto. The end effector assembly includes a pair of opposing jaw members configured to move from an open, spread position to a closed, grasping position; creating at least one opening in the patient for inserting the forceps therein; inserting through the opening and manipulating jaw members of the forceps to grasp a portion of a first heart valve leaflet and a portion of a second heart valve leaflet therebetween; activating the forceps to close the jaw members about the leaflet portions under a working pressure, applying radiofrequency energy to the jaw members to seal the portion of the first heart valve leaflet to the portion of the second heart valve leaflet.Type: ApplicationFiled: May 25, 2007Publication date: April 3, 2008Inventors: E. Christopher Orton, Michael C. Moses, Amy Denham, Jeffrey Townsend
-
Publication number: 20020022878Abstract: A method for producing a non-immunogenic and durable living graft involves the recellularization of a decellularized heart valve allograft or xenograft by recipient cells after implantation of such graft into a living patient. Decellularized allograft or xenograft grafts which have not been exposed to a cytotoxic environment are treated with either chemotactic factors or cell adhesion factors, or both, to retain desirable recipient cells into the tissue graft after implantation.Type: ApplicationFiled: July 20, 2001Publication date: February 21, 2002Inventor: E. Christopher Orton
-
Patent number: 5863296Abstract: Tissue which is suitable for transplant is treated with a growth factor and cells which populate the tissue and native cells must be removed, they cannot be "masked" reduce immunogenicity; this increases the longevity of the tissue upon transplant. The preferred growth factor is basic fibroblast growth factor, and the preferred cells are fibroblasts. The tissue can be an allograft or xenograft taken from a cow, pig or other mammal.Type: GrantFiled: June 5, 1995Date of Patent: January 26, 1999Assignee: Colorado State University Research FoundationInventor: E. Christopher Orton
-
Patent number: 5855617Abstract: Tissue which is suitable for transplant is treated with a growth factor and cells which populate the tissue and native cells must be removed, they cannot be "masked" reduce immunogenicity; this increases the longevity of the tissue upon transplant. The preferred growth factor is basic fibroblast growth factor, and the preferred cells are fibroblasts. The tissue can be an allograft or xenograft taken from a cow, pig or other mammal.Type: GrantFiled: September 12, 1996Date of Patent: January 5, 1999Assignee: Colorado State University Research FoundationInventor: E. Christopher Orton
-
Patent number: 5772695Abstract: Tissue which is suitable for transplant is treated with a growth factor and cells which populate the tissue and native cells must be removed, they cannot be "masked" reduce immunogenicity; this increases the longevity of the tissue upon transplant. The preferred growth factor is basic fibroblast growth factor, and the preferred cells are fibroblasts. The tissue can be an allograft or xenograft taken from a cow, pig or other mammal.Type: GrantFiled: February 26, 1993Date of Patent: June 30, 1998Assignee: Colorado State University Research FoundationInventor: E. Christopher Orton
-
Patent number: 5192312Abstract: Tissue which is suitable for transplant is treated with a growth factor and cells which populate the tissue and native cells must be removed, they cannot be "masked" reduce immunogenicity; this increases the longevity of the tissue upon transplant. The preferred growth factor is basic fibroblast growth factor, and the preferred cells are fibroblasts. The tissue can be an allograft or xenograft taken from a cow, pig or other mammal.Type: GrantFiled: March 5, 1991Date of Patent: March 9, 1993Assignee: Colorado State University Research FoundationInventor: E. Christopher Orton